Lotronex and the FDA: a fatal erosion of integrity.
Horton
R
R
The Lancet, WC1X 8RR, London, UK.
D002243:Carbolines / Q000009:adverse effects* / Q000627:therapeutic use; D017091:Colitis, Ischemic / Q000139:chemically induced* / Q000401:mortality*; D003109:Colonic Diseases, Functional / Q000188:drug therapy; D017277:Drug Approval; D004345:Drug Industry; D004335:Drug and Narcotic Control; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D033161:Government Regulation; D006801:Humans; D008297:Male; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D014481:United States; D014486:United States Food and Drug Administration
D002243:Carbolines; D005765:Gastrointestinal Agents; C090840:alosetron